Royalty Pharma plc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation United Kingdom
Business Address 110 EAST 59TH STREET, NEW YORK, NY, 10022
Mailing Address 110 EAST 59TH STREET, NEW YORK, NY, 10022
Phone (212) 883-0200
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025 FY
$2.38B
Revenue
$1.13B
Net Income
$19.62B
Total Assets
$929.03M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 10-K Annual financial report | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
Annual Reports
10-K February 11, 2026
- Royalty Pharma reported a robust year with total royalty receipts surging 15% to $2.8 billion and net income increasing 20% to $1.1 billion.
- The company strategically expanded its portfolio with $800 million in new investments, diversifying its asset base with high-growth products like Evrysdi and Trelegy.
Insider Trading
STRONG SELL 3 insiders
43 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.